News
Antidepressant shows early promise for mild COVID-19
The findings on fluvoxamine “need to be interpreted as hypothesis generating rather than as a demonstration of efficacy,” the study authors wrote...
News
FDA clears smartphone app to interrupt PTSD-related nightmares
NightWare was tested in a 30-day randomized, sham-controlled trial of 70 patients.
News
Add-on atypicals for depression carry ‘substantial’ death risk
“We don’t know the mechanisms of the increased mortality risk, but cardiac and infectious causes are leading candidates,” said Dr. Tobias Gerhard...
News
Brain imaging reveals a neural basis for partisan politics
Despite watching the same videos related to immigration policy, neural responses differed between liberals and conservatives.
News
Add-on psychotherapy a win in bipolar disorder
It’s increasingly recognized that drug therapy alone cannot prevent recurrences of bipolar disorder or fully alleviate post-episode symptoms, the...
News
COVID-19: A second wave of mental illness 'imminent'
Each COVID-19 death leaves about nine family members bereaved, note Dr. Naomi Simon and coauthors.
News
Migraine nerve stimulation device now available over the counter
The device stimulates the trigeminal nerve using a reusable self-adhesive electrode placed on the forehead.
News
AHA issues new scientific statement on heart health for LGBTQ adults
The AHA urges routine check of cardiovascular health and efforts to combat discrimination in the health care setting for LGBTQ adults.
News
AHA scientific statement highlights cardiorenal benefit of new diabetes drugs
SGLT2 inhibitors and GLP-1 receptor agonists should be considered in people with type 2 diabetes and chronic kidney disease to protect against...
News
OTC ‘brain boosters’ may pose serious risks, experts say
“We know very little about what is actually in these products.”